Cost-effectiveness of cetuximab for colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Taehwan | - |
dc.contributor.author | Choi, Chang-ju | - |
dc.contributor.author | Choi, Yeera | - |
dc.contributor.author | Suh, Dong-Churl | - |
dc.date.available | 2019-03-08T11:59:20Z | - |
dc.date.issued | 2016-12 | - |
dc.identifier.issn | 1473-7167 | - |
dc.identifier.issn | 1744-8379 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6398 | - |
dc.description.abstract | Introduction: Cetuximab is a novel biological agent with superior therapeutic efficacy for colorectal cancer treatment. This study aimed to systematically review the existing evidence related to the cost-effectiveness of cetuximab.Areas covered: Using Medline and Cochrane Database of Systematic Reviews, a total of 12 articles were identified. Previous studies have shown mixed results on the cost-effectiveness of first-line cetuximab combined with FOLFIRI (5-Fluorouracil, leucovorin, irinotecan). However, cetuximab-irinotecan therapy as third-line treatment has consistently been found to be cost-ineffective compared to best supportive care or no third-line therapy. The Kristen-rat-Sarcoma-viral-oncogene (KRAS) testing strategy prior to cetuximab use has been reported as cost-effective compared with the cetuximab-containing strategy without KRAS testing.Expert commentary: The results should be interpreted with consideration of the specific healthcare settings in which cetuximab use was evaluated. Future studies are expected to examine the economic value of cetuximab compared with other newly approved biologic products. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Cost-effectiveness of cetuximab for colorectal cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1080/14737167.2016.1245618 | - |
dc.identifier.bibliographicCitation | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, v.16, no.6, pp 667 - 677 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000390683900005 | - |
dc.identifier.scopusid | 2-s2.0-84992116208 | - |
dc.citation.endPage | 677 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 667 | - |
dc.citation.title | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | - |
dc.citation.volume | 16 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Cost-effectiveness | - |
dc.subject.keywordAuthor | cetuximab | - |
dc.subject.keywordAuthor | colorectal cancer | - |
dc.subject.keywordAuthor | pharmacoeconomics | - |
dc.subject.keywordAuthor | outcomes research | - |
dc.subject.keywordPlus | K-RAS MUTATION | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY THERAPY | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | BRAF MUTATION | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTOR | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Policy & Services | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.